## A three-dimensional vessel-on-chip model to study Puumala orthohantavirus pathogenesis

Danny Noack<sup>1</sup>, Anouk van Haperen<sup>1</sup>, Mirjam C.G.N. van den Hout<sup>2,3</sup>, Eleanor M. Marshall<sup>1</sup>, Rosanne W. Koutstaal<sup>1</sup>, Vincent van Duinen<sup>4</sup>, Lisa Bauer<sup>1</sup>, Anton Jan van Zonneveld<sup>4</sup>, Wilfred F.J. van IJcken<sup>2,3</sup>, Marion P.G. Koopmans<sup>1</sup>, and Barry Rockx<sup>1</sup>

## Affiliations

1. Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands

- 2. Department of Cell Biology, Erasmus University Medical Center, Rotterdam, the Netherlands
- 3. Center for Biomics, Erasmus University Medical Center, Rotterdam, the Netherlands

4. Department of Internal Medicine, division of Nephrology and the Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands

## Corresponding author

Barry Rockx, PhD, Department of Viroscience, Erasmus MC, 's-Gravendijkwal 230, 3015 CE, Rotterdam, the Netherlands. E-mail: <u>b.rockx@erasmusmc.nl</u>

The supplementary information includes:

Video S1 Fig. S1 Video S1 Three-dimensional representation of a perfused vessel-on-chip. Representative three-dimensional (3D) render of a vessel-on-chip, demonstrating the 3D architecture tube-like structures of an EC monolayer. Nuclei are expressed in grey and VE-cadherin in red. Z-stack images were obtained from confocal microscopy and rendered with Dragonfly software.



Fig. S1 RNA-Seq analyses of ECs cultured in static 2D and vessel-on-chip models upon TNFa treatment. (A) Principal component analysis (PCA) plot based on vst normalized counts of mock- and 24 hours 100 ng/ml tumor necrosis factor alpha (TNFα)-treated samples. (B) Venn diagram comparing significantly upregulated and downregulated genes in response to TNFα treatment in static 2D and vessel-on-chip EC cultures. For Volcano plots, grey dots represent genes which expressions neither significantly altered nor exceeded the fold change cut-off. Blue dots represent significantly altered genes that did not exceed the fold change cut-off. Green dots represent genes which expressions were not significantly altered, but exceeded the fold change cut-off. Red dots represent genes with significantly altered expressions that also exceeded the fold change cut-off. (C) Volcano plot demonstrating significantly upregulated and downregulated gene expressions following TNFα-treatment compared to mock-treated cells in static 2D-cultured ECs. (D) Volcano plot demonstrating significantly upregulated and downregulated gene expressions following TNFα-treatment compared to mock-treated cells in vessel-on-chip-cultured ECs. (E) Bar charts demonstrating top 25 highest fold changes of common significantly upregulated genes due to TNFa treatment, ranked on the fold change in static 2D cultures. (F) TNFα-induced transcriptomic gene expression profile overview for ECs cultured in static 2D or vessels-on-chip. Balloon plot displaying significantly (Benjamini-Hochberg adjusted P-value < 0.05) enriched GO-terms upon TNFα treatment. Size of the balloon represents the number of differentially expressed genes within a GO-term (DGE inTerm) while the color of the balloon represents the negative base-10 logarithm of the P-value. GeneRatio on the x-axis is the number of differentially expressed genes divided by the total number of genes involved in the GO-term. Significant GOterms were ranked on highest GeneRatio, displaying the top 10 common pathways, and top 5 for unique pathways for vesselon-chip and static 2D cultures. Blue font indicates that the enrichment of the GO-term was mainly based on downregulated genes. For illustrative purposes, GO-terms were cut-off to 90 characters, complete term: GO:0016709 - oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen.